Riccardo BragliaiOnctura Announces First Subject Dosed in Healthy Volunteer Study of Next Generation Autotaxin…* IOA-289 first ATX inhibitor to progress to clinic in oncologyDec 17, 2021Dec 17, 2021
Riccardo BragliaTHE CANCER AND SUPPORTIVE CARE PRODUCTS AT HELSINNFor over 40 years, the Switzerland based pharmaceutical and biotechnology company Helsinn has been committed to providing cutting edge…Nov 5, 2021Nov 5, 2021
Riccardo BragliaHelsinn and Fosun Pharma sign exclusive license and distribution agreements for Aloxi®, Akynzeo®…Lugano, Switzerland — Shanghai, China, October 12, 2021 — Helsinn Group (“Helsinn”), a Swiss Biopharmaceutical Group with an innovative…Oct 12, 2021Oct 12, 2021
Riccardo BragliaHelsinn Group and BridgeBio Pharma’s Affiliate QED Therapeutics Announce Health Canada Conditional…LUGANO, Switzerland, and PALO ALTO, CA, September 29, 2021 — Helsinn Group and BridgeBio Pharma, Inc. (Nasdaq: BBIO), through its…Sep 29, 2021Sep 29, 2021
Riccardo BragliaArt Collecting — From Ancient Civilizations to Contemporary ArtPeople buy art to appreciate it and enhance their life and environment. Ancient Greek and Egyptian civilizations started collecting art…Jul 30, 2021Jul 30, 2021
Riccardo BragliaSwiss-Italian Pharmaceutical Entrepreneur Riccardo BragliaThe chief executive officer and group vice chairman of the board of Helsinn Group in Lugano, Switzerland, Riccardo Braglia has spent 35…Apr 7, 2021Apr 7, 2021
